Prostate Cell News Volume 5.43 | Nov 14 2014

SYK Is a Candidate Kinase Target for the Treatment of Advanced Prostate Cancer
Scientists report the identification of the spleen kinase SYK as a mediator of metastatic dissemination in zebrafish and mouse xenograft models of human prostate cancer. While SYK has not been implicated previously in this disease, they found that its expression is upregulated in human prostate cancers and associated with malignant progression. [Cancer Res] Abstract

Radiation Protection of the Gastrointestinal Tract and Growth Inhibition of Prostate Cancer Xenografts by a Single Compound
RTA 408 uniformly inhibited growth of established CWR22Rv1, LNCaP/C4-2B, PC3, and DU145 xenografts either alone or combined with radiation. Antitumor effects in vivo were associated with reduced proliferation and intratumoral apoptosis and with inhibition of NF-κB-dependent transcription in PC3 cells. [Mol Cancer Ther] Abstract | Press Release

EGFR and IGF-1R in Regulation of Prostate Cancer Cell Phenotype and Polarity: Opposing Functions and Modulation by T-Cadherin
Scientists found that T-cadherin overexpression in malignant and benign prostatic epithelial cell lines or silencing in the BPH-1 cell line, respectively, promoted or inhibited migration and spheroid invasion in collagen I gel and Matrigel. Epidermal growth factor receptor (EGFR) and IGF factor-1 receptor (IGF-1R) were identified as mediators of T-cadherin effects. [FASEB J] Abstract

Arctigenin in Combination with Quercetin Synergistically Enhances the Anti-Proliferative Effect in Prostate Cancer Cells
Androgen-dependent LAPC-4 and LNCaP prostate cancer cells were treated with low doses of arctigenin and quercetin alone or in combination for 48 hours. The anti-proliferative activity of arctigenin was 10-20 fold stronger than quercetin in both cell lines. [Mol Nutr Food Res] Abstract

Fenofibrate Enhances Barrier Function of Endothelial Continuum within the Metastatic Niche of Prostate Cancer Cells
Researchers qualitatively and quantitatively estimated the effect of 25 μM fenofibrate on the events which accompany prostate carcinoma cell diapedesis, with the special emphasis on endothelial cell mobilization. [Expert Opin Ther Targets] Abstract

Effects of Luteinizing Hormone Receptor Signaling in Prostate Cancer Cells
Luteinizing hormone receptor (LHR) mRNA and protein expression was evaluated in LNCaP prostate cancer (PC) cells treated with LHR-siRNA. MTS assay was used to measure the effect of LHR-siRNA on proliferation in LNCaP and 22RV1 PC cells. [Prostate] Abstract

3D Cultures of Prostate Cancer Cells Cultured in a Novel High-Throughput Culture Platform Are More Resistant to Chemotherapeutics Compared to Cells Cultured in Monolayer
Scientists have developed a microwell platform and surface modification protocol to enable high throughput manufacture of 3D cancer aggregates. They used this novel system to characterize prostate cancer cell microaggregates, including growth kinetics and drug sensitivity. [PLoS One] Full Article

Knockdown of Cancerous Inhibitor of Protein Phosphatase 2A May Sensitize Metastatic Castration-Resistant Prostate Cancer Cells to Cabazitaxel Chemotherapy
To determine whether cancerous inhibitor of protein phosphatase 2A (CIP2A) serves as a potential therapeutic target of human prostate cancer (PCa), researchers utilized small interference RNA to knock down CIP2A expression in human PCa cells and analyzed their phenotypic changes. [Tumor Biol] Abstract

Evidence of Histidine and Aspartic Acid Phosphorylation in Human Prostate Cancer Cells
Scientists developed a method to identify previously undetected histidine and aspartic acid phosphorylations in a human prostate cancer progression model. A phosphoproteome of a cell line model is presented, with correlation of modified protein expression between the three states of cancer: non-tumorigenic, tumorigenic, and metastatic cells. [Naunyn Schmiedebergs Arch Pharmacol] Abstract

CLINICAL RESEARCH

Tumor Genomic and Microenvironmental Heterogeneity for Integrated Prediction of 5-Year Biochemical Recurrence of Prostate Cancer: A Retrospective Cohort Study
Clinical prognostic groupings for localized prostate cancers are imprecise, with 30-50% of patients recurring after image-guided radiotherapy or radical prostatectomy. Investigators tested combined genomic and microenvironmental indices in prostate cancer to improve risk stratification and complement clinical prognostic factors. [Lancet Oncol] Full Article | Press Release

Can Urinary PCA3 Supplement PSA in the Early Detection of Prostate Cancer?
To improve early-detection biopsy decisions, scientists conducted a prospective validation trial to assess the diagnostic performance of the prostate cancer antigen 3 (PCA3) urinary assay for the detection of prostate cancer among men screened with prostate-specific antigen (PSA). [J Clin Oncol] Abstract

Change in PSA Velocity Is a Predictor of Overall Survival in Men with Biochemically-Recurrent Prostate Cancer Treated with Nonhormonal Agents: Combined Analysis of Four Phase II Trials
Researchers performed a combined retrospective analysis of 146 men with biochemically-recurrent prostate cancer treated on Phase II trials using one of four investigational drugs: lenalidomide, marimastat, ATN-224 and imatinib. They examined factors influencing overall survival, including within subject changes in PSA kinetics, before and six months after treatment initiation. [Prostate Cancer Prostatic Dis] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.

Innocrin Pharmaceuticals and the Prostate Cancer Foundation (PCF) Join Forces for Innovative Phase II Clinical Study
Innocrin Pharmaceuticals, Inc. announced its participation in a multi-center Phase II clinical study of VT-464 in prostate cancer patients resistant to next-generation androgen receptor signaling inhibitors Zytiga^® or Xtandi^®. [Innocrin Pharmaceuticals, Inc.] Press Release

AMC Health Partners with Icahn School of Medicine on Televideo-Enabled Prostate Cancer Clinical Trial
AMC Health announced the first patient enrolled in a prostate cancer clinical trial deploying televideo, at Mount Sinai’s Icahn School of Medicine in Manhattan. The trial is testing whether the antidiabetic medication metformin may slow the progression of recurrent prostate cancer. [AMC Health] Press Release

Oncoethix Starts Phase Ib Trials of OTX015 in the Treatment of Advanced Solid Tumors (OTX015_107) and Glioma (OTX015_108)
Oncoethix announced that the first patient has been enrolled in an international, open-label, non-randomized, multicenter Phase Ib trial of OTX015 in advanced solid tumors. [Oncoethix (Business Wire)] Press Release

From our sponsor:
Interested in assays for human mammary stem and progenitor cells? Request your free wallchart.

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the prostate cell community.

Postdoctoral Position – Prostate Cancer and Prostatic Diseases (Louisiana State University)

Postdoctoral Associate – Biomarkers Associated with Prostate Cancer (Duke Molecular Physiology Institute)

Head of Cellular and Molecular Therapies Laboratory (NHS Blood & Transplant)

Postdoctoral Fellow – Metabolomics and Prostate Cancer (University of Maryland)

Senior Research Associate – Nanomedicine (University of East Anglia)

Postdoctoral Fellow – Role of Deregulated PTEN/FOXO1 Pathway in Prostate Cancer (Mayo Clinic)

Postdoctoral Fellow – Oncology (Johnson & Johnson Pharmaceutical Research & Development)

Postdoctoral Fellow – Prognostic Biomarkers for Prostate Cancer (McGill University)

Physician Scientist – Prostate Cancer Genomics (University of Chicago)

Tenure Track Position – Cancer Biology (Wake Forest Baptist Medical Center)

Scientist – Prostate Cell Research (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.